< Back

October, 2017

Commercial Deficiency Due to Limited Market Access is a Growing Concern for Biopharmaceutical Companies

HTA Impact on Global Access    |    Research Released September 2017

Commercial Deficiency Due to Limited Market Access is a Growing Concern for Biopharmaceutical Companies

The vast majority of HTA agencies reject or restrict the adoption of new medicines.

Biopharmaceutical companies must devote exceptional efforts and resources to demonstrably prove the value of their products to HTA agencies and achieve favorable coverage.

Variations in HTA Recommendations by Country

Download the research slide

 

These and other findings can be found in Health Strategies Group’s recently released research Global Market Access HTA Decision Making Landscape.

Key topics covered in this research:

  • HTA agency assessment and interpretation of submitted evidence
  • Drivers that shape positive and negative coverage recommendations
  • Rationale and patterns behind HTA coverage recommendations
  • Real-world category-specific case studies
  • Implications and key takeaways for biopharmaceutical companies

Download Research Agenda

 

Visit our HTA Impact on Global Access webpage to learn more about this research.

Disclaimer

 

Please complete the form to have this document sent to your email.

 

Please complete the form to have this document sent to your email.